The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials. With the help of the Biomarkers Consortium ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback